- Home
- AZN
AZN
AstraZeneca PLC
as 07-26-2024 4:00pm EST
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, immunology and rare diseases. The majority of sales come from international markets with the United States representing close to one third of its revenue.
| Founded: | 1992 | Country: | United Kingdom |
| Employees: | N/A | City: | N/A |
| Market Cap: | 245.9B | IPO Year: | 1993 |
| Target Price: | $87.25 | AVG Volume (30 days): | 3.5M |
| Analyst Decision: | Buy | Number of Analysts: | 7 |
| Dividend Yield: | Dividend Payout Frequency: | Semi-Annual | |
| EPS: | 2.06 | EPS Growth: | 4.29 |
| 52 Week Low/High: | $60.47 - $80.86 | Next Earning Date: | 07-25-2024 |
| Revenue: | $49,133,000,000 | Revenue Growth: | 10.45% |
| Revenue Growth (this year): | 16.02% | Revenue Growth (next year): | 7.31% |
Latest AstraZeneca PLC News
AZN Breaking Stock News: Dive into AZN Ticker-Specific Updates for Smart Investing
Pharmaceutical Technology
7 hours ago
FDA committee proposes overhaul of perioperative lung cancer trials
Motley Fool
8 hours ago
3 Surprisingly Underrated Stocks to Buy Right Now
Zacks
10 hours ago
Pharma Stock Roundup: AZN, SNY, ABBV Q2 Earnings, PFE & MRK's Positive Pipeline News
Argus Research
13 hours ago
Analyst Report: AstraZeneca PLC
Argus Research
13 hours ago
Market Digest: SNY, CMCSA, CMG, KLAC, KMB, RCL, UPS, AZN, MSCI, TSLA
Simply Wall St.
17 hours ago
Top 3 UK Stocks Estimated To Be Undervalued In July 2024
Yahoo Finance Video
19 hours ago
AstraZeneca CEO talks dual supply chain strategy
Investor's Business Daily
a day ago
AstraZeneca Says It Has A 'Powerful' — And Differentiated — Approach To Obesity Treatment
Compare AZN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "AZN AstraZeneca PLC - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.